We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen
BIIB 261.65-2.2%3:59 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mopgcw who wrote (1648)5/14/2009 1:03:03 PM
From: kenhott   of 1685
Mr. CI is in it for himself. Maybe with big pharmas narrowing their business focuses, splitting the company in two will get more bidders than the entire company as a whole??

OT-not Biogen- Killing two birds with one stone... <reply>

I don't really follow the company. But the drug is a pretty good one and it is pretty crazy that the law firm screwed up the filing. I would guess that the generics are using paragraph III to get to market, and as far as I know there is no way to tell which company has filed till after action by the FDA.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext